Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast Cancer

Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast Cancer

Show other versions (1)

Bibliographic Details
Main Authors:	Joelle Zambrano, Elizabeth S. Yeh
Format:	Article
Language:	English
Published:	SAGE Publishing 2016-03-01
Series:	Breast Cancer: Basic and Clinical Research
Online Access:	http://www.la-press.com/autophagy-and-apoptotic-crosstalk-mechanism-of-therapeutic-resistance--article-a5456

Similar Items

Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast Cancer
by: Joelle Zambrano, et al.
Published: (2016-01-01)

Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications
by: Sara S Bashraheel, et al.
Published: (2023-06-01)

Co-Targeting of JNK and HUNK in Resistant HER2-Positive Breast Cancer.
by: Kendall Phelps-Polirer, et al.
Published: (2016-01-01)

Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
by: Mark Pegram, et al.
Published: (2023-05-01)

HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
by: Sonia Pernas, et al.
Published: (2019-03-01)

Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer
by: Andrew T Baker, et al.
Published: (2014-12-01)

Pyrotinib and chrysin synergistically potentiate autophagy in HER2-positive breast cancer
by: Xiaoxiao Liu, et al.
Published: (2023-12-01)

Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies
by: Xiaofan Wu, et al.
Published: (2022-09-01)

Crosstalk between PRLR and EGFR/HER2 Signaling Pathways in Breast Cancer
by: Raghuveer Kavarthapu, et al.
Published: (2021-09-01)

The role of HER4 in relation to trastuzumab resistance and prognosis in HER2 positive breast cancer
by: Mohd Nafi, SN
Published: (2014)

Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer
by: Angelica Ferrando-Díez, et al.
Published: (2022-07-01)

The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
by: Zaid Sirhan, et al.
Published: (2022-07-01)

The Role of Autophagy in Liver Cancer: Crosstalk in Signaling Pathways and Potential Therapeutic Targets
by: Jianzhou Cui, et al.
Published: (2020-11-01)

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents
by: Zhen-hao Wang, et al.
Published: (2022-10-01)

Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab.
by: Alejandro Vazquez-Martin, et al.
Published: (2009-01-01)

The crosstalk between ferroptosis and autophagy in cancer
by: Xiaodi Lv, et al.
Published: (2023-12-01)

Crosstalks between inflammasome and autophagy in cancer
by: Chaeuk Chung, et al.
Published: (2020-07-01)

Leptin/HER2 crosstalk in breast cancer: <it>in vitro</it> study and preliminary <it>in vivo</it> analysis
by: Molino Annamaria, et al.
Published: (2008-10-01)

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
by: Yi Ding, et al.
Published: (2018-10-01)

Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now
by: Xiaowei Qi, et al.
Published: (2023-10-01)

Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches
by: Ayoub NM, et al.
Published: (2019-01-01)

Therapeutic resistance and optimal drug sequencing in HER2-positive metastatic breast cancer: unmet needs and future perspectives
by: Francesco Schettini, et al.
Published: (2024-01-01)

The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells
by: Peipei Liu, et al.
Published: (2020-06-01)

Crosstalk of Autophagy and Apoptosis
by: Maurizio Sorice
Published: (2022-04-01)

Immunotherapy for HER-2 positive breast cancer
by: Tingting Yang, et al.
Published: (2023-03-01)

Crosstalk between Autophagy and Inflammatory Processes in Cancer
by: Eun-Ji Lee, et al.
Published: (2021-08-01)

The crosstalk between sonodynamic therapy and autophagy in cancer
by: Yujie Zhang, et al.
Published: (2022-08-01)

Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
by: Ami Hori, et al.
Published: (2019-08-01)

Crosstalk between autophagy and metabolic regulation of (CAR) T cells: therapeutic implications
by: Ahmad Reza Panahi Meymandi, et al.
Published: (2023-08-01)

The roles of autophagy, ferroptosis and pyroptosis in the anti-ovarian cancer mechanism of harmine and their crosstalk
by: Jun Zhu, et al.
Published: (2024-03-01)

Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies
by: Laurence Lousberg, et al.
Published: (2016-11-01)

Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.
by: David Lesniak, et al.
Published: (2013-01-01)

Pro-apoptotic property of phytocompounds from Naringi crenulata in HER2+ breast cancer cells in vitro
by: Sugumari Vallinayagam, et al.
Published: (2021-01-01)

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
by: Fei Xing, et al.
Published: (2023-01-01)

HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
by: Kaho Tateishi, et al.
Published: (2023-11-01)

Autophagy and Autoimmunity CrossTalks
by: Abhisek eBhattacharya, et al.
Published: (2013-04-01)

Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers
by: Yang Zheng, et al.
Published: (2023-05-01)

Immunological Landscape of HER-2 Positive Breast Cancer
by: Santiago Moragon, et al.
Published: (2022-06-01)

Immunotherapies against HER2-Positive Breast Cancer
by: Santiago Duro-Sánchez, et al.
Published: (2023-02-01)

Educational Case: HER-2 Positive Breast Cancer
by: Julia Jennings MD, et al.
Published: (2021-09-01)